Posted by Researchers in Japan have developed a promising new drug delivery platform that not only carries medicines directly to bone, but also suppresses the activity of osteoclasts—the cells responsible for breaking down bone.
The discovery could open the door to safer and more effective treatments for osteoporosis, bone metastases from cancer, osteonecrosis, bone infections, and other diseases involving excessive bone loss.
Why Better Bone Treatments Are Needed?
Osteoporosis is a condition in which bones become weak and fragile due to loss of bone mass and changes in bone structure. In Japan alone, an estimated 15.9 million people are affected, and the number continues to rise as the population ages. Current osteoporosis drugs, especially bisphosphonates, can slow bone loss effectively. However, long-term use is associated with rare but serious side effects, including:
- Medication-related osteonecrosis of the jaw (MRONJ)
- Atypical femur fractures (AFF)
Because of these concerns, scientists have been searching for safer alternatives—especially for patients who require years of treatment.
A Dual-Function Drug Delivery System
A research team led by Professor Tatsuya Yoshizawa of Kyoto Prefectural University of Medicine and Associate Professor Mitsuhiro Yoshikawa of Osaka Dental University has developed a new bone-targeting drug delivery system based on phosphorylated beta-cyclodextrin, abbreviated as β-CDP. The researchers modified beta-cyclodextrin by adding phosphate groups. These phosphate groups have a strong attraction to hydroxyapatite, the mineral that makes up most of bone.
As a result, β-CDP has two important functions:
- It can deliver drugs specifically to bone.
- It can directly reduce bone resorption by osteoclasts.
This makes β-CDP more than just a carrier—it may become an active treatment in its own right.
How the New System Targets Bone
In laboratory experiments, β-CDP strongly bound to hydroxyapatite-coated surfaces, suggesting it could attach effectively to bone tissue. The team then injected fluorescently labeled β-CDP into mice. Imaging showed that the compound accumulated in bone within 30 minutes and remained there for at least one day. Importantly, its presence began to decline after two days. This relatively short residence time may be important. Existing bisphosphonate drugs can remain in bone for years, which may contribute to long-term side effects. In contrast, β-CDP appears to leave the bone much more quickly. The researchers also confirmed that β-CDP can carry other compounds inside its molecular structure and transport them selectively to bone.
A Different Way to Stop Bone Loss
Unlike bisphosphonates, β-CDP does not kill osteoclasts or prevent them from forming. Instead, it interferes with the osteoclasts’ ability to dissolve bone. The team found that β-CDP appears to disrupt the localization of a vacuolar proton pump in specialized regions of the osteoclast cell membrane known as lipid rafts. This proton pump is essential for osteoclasts to break down bone. By blocking this process, β-CDP reduced bone resorption without harming the cells themselves. That distinction is important because preserving osteoclast viability while lowering their activity could reduce the risk of serious complications seen with current therapies.
Strong Results in Osteoporosis Model Mice
The researchers tested β-CDP in mice with osteoporosis caused by ovary removal, a common model of postmenopausal bone loss.
Mice treated with β-CDP showed:
- Much less bone loss
- Improved trabecular bone width and number
- Nearly normal bone structure compared with untreated mice
The treatment was given twice a week for five weeks.
The team also tested the compound in a model of age-related osteoporosis, which develops through a different biological mechanism. Female mice receiving β-CDP once a week for four months had significantly greater bone mass and thicker trabeculae in the femur. These findings suggest that β-CDP may work across multiple forms of osteoporosis.
Potential Beyond Osteoporosis
Perhaps the most exciting aspect of this technology is that β-CDP could serve as a general platform for bone-targeted medicine.
Because the molecule can carry drugs directly to bone, it may be possible to load it with:
- Anti-cancer drugs for bone metastases
- Pain medications
- Anti-inflammatory drugs
- Antibiotics for bone infections
At the same time, β-CDP itself may suppress bone destruction. This combination could allow doctors to treat bone diseases more precisely while reducing harmful effects elsewhere in the body.
Looking Ahead
The study suggests that phosphorylated beta-cyclodextrin may become a safer alternative to current bone-resorption inhibitors, especially for patients who need long-term treatment.
Although more research and clinical testing will be necessary before the technology reaches patients, the results are highly encouraging.
If future studies confirm these findings, β-CDP could become the foundation for a new generation of bone-targeted therapies—ones that both deliver medicine where it is needed and protect the skeleton at the same time.
Study details
Yoshikawa Y, Tamura A, Higashi T, Hirai Y, Tsuda S, Domae E, Taniguchi M, Ikeo T, Yoshizawa T. Bone-targeting β-cyclodextrin phosphate has anti-resorptive activity and thereby prevents osteoporosis. J Control Release. 2026 Apr 10;392:114735. doi: 10.1016/j.jconrel.2026.114735. Epub 2026 Feb 16. PMID: 41707771.